Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00841789 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
A Phase 2 study of Kawasaki Disease and Mucocutaneous Lymph Node Syndrome, sponsored by Michael Portman.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
- 8
- Study locations
NCT00841789 is a Phase 2 study of Kawasaki Disease and Mucocutaneous Lymph Node Syndrome that has completed, run by Michael Portman. The registered enrollment target is 205 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT00841789, a Phase 2 study of Kawasaki Disease and Mucocutaneous Lymph Node Syndrome, has completed, sponsored by Michael Portman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine whether Etanercept (Enbrel) when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawasaki Disease. Funding Source- FDA/OOPD
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Etanercept
Study Locations (8)
New York
- Feinstein Institute for Medical Rsearch - New Hyde Park
- Columbia University Medical Center - New York
- Montefiore Medical Center - The Bronx
Texas
- Texas Children's Hospital - Houston
Utah
- Primary Children's Medical Center - Salt Lake City
Washington
- Seattle Children's Hospital - Seattle
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Quebec
- Sainte-Justine Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-03 |
| Est. Completion | 2018-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00841789
The ClinicalTrials.gov registry entry for NCT00841789 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael Portman, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kawasaki Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00841789 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT00841789 about?
NCT00841789 is a clinical study titled "A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease". The purpose of this study is to determine whether Etanercept (Enbrel) when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawasaki Disease. Funding Source- FDA/OOPD
What is the current status of trial NCT00841789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-03. Estimated completion is 2018-08-30.
What conditions does trial NCT00841789 study?
This clinical trial studies the following conditions: Kawasaki Disease, Mucocutaneous Lymph Node Syndrome.
What interventions are being tested in trial NCT00841789?
The interventions under investigation include: Placebo (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT00841789?
This trial is sponsored by Michael Portman, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00841789 being conducted?
This trial has 8 study locations across New York, Texas, Utah, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kawasaki Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.